Topic: tax reform

Pharma authorized tens of billions of dollars' worth of share buybacks before or shortly after tax reform, and that irked an industry veteran.

Takeda hasn’t even approached Shire’s board with a buyout offer yet, but competing bidders could jump in quickly, thanks to U.K. takeover rules.

Pfizer’s board of directors is providing rich incentives to keep CEO Ian Read on board as the company navigates a host of challenges.

Some drugmakers reap far more savings from tax reform than others—and some will actually have to pay more. Here's our report card.

Merck is projecting a flat tax rate this year as many of its peers expect to see a benefit.

Several pharma companies have thrilled investors with their sunny predictions—but not Amgen.

The way Pfizer CEO Ian Read sees it, congratulations are well deserved for his company's tax reform lobbying efforts.

Pfizer’s finally getting what it always wanted in U.S. tax reform. And now, all eyes are on what it will do next.

Novartis and Bayer executives were among a list of attendees at a private dinner in Davos with U.S. President Donald Trump.